I assume they (as jbog noted, most ex-US countries), will pay for the a new, expensive, treatment with xxx efficacy only if certain patients fail (or have a high risk of failing) the existing less expensive treatment with xx efficacy.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.